1. Testing of affected individual (proband) with hereditary leiomyomatosis and renal cell cancer (HLRCC)
or other FH deficiency disorder where the individual +/- family history meets one of the following criteria.

The proband has:
a. Type 2 papillary, HLRCC associated RCC (WHO pathology definition) OR tubulo-papillary renal tumour at any age, OR
b. Two of: cutaneous leiomyomata, renal tumour (any histology) , OR uterine leiomyomata with
classic histological features < 40 years OR c. Cutaneous leiomyomata AND one first / second / third degree relative with renal tumour, OR d. Cutaneous leiomyomata AND two first / second / third degree relatives with cutaneous leiomyomata OR uterine leiomyomata with classic histological features < 40 years, OR e. Uterine leiomyomata with classic histological features (age <40) OR f. Multiple cutaneous leiomyomata 2. Deceased affected individual (proband) where (i) the individual +/- family history meets one of the above criteria, (ii) appropriate tissue is available (tumour or normal), and (iii) no living affected individual is available for genetic testing NOTE: Cutaneous leiomyomata should be histologically confirmed; uterine leiomyomata and renal tumours should be medically documented Genetic testing may occasionally be appropriate outside these criteria following discussion at a specialist MDT with a cancer geneticist present